Equities analysts expect Flexion Therapeutics Inc (NASDAQ:FLXN) to post sales of $1.29 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Flexion Therapeutics’ earnings, with estimates ranging from $900,000.00 to $1.68 million. The company is scheduled to report its next earnings report on Thursday, March 8th.
According to Zacks, analysts expect that Flexion Therapeutics will report full year sales of $1.29 million for the current year, with estimates ranging from $900,000.00 to $1.68 million. For the next year, analysts expect that the business will post sales of $25.45 million per share, with estimates ranging from $17.50 million to $41.70 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Flexion Therapeutics.
A number of research analysts recently commented on FLXN shares. BMO Capital Markets reaffirmed a “buy” rating on shares of Flexion Therapeutics in a report on Friday, August 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price target (up previously from $34.00) on shares of Flexion Therapeutics in a report on Thursday, August 10th. Wells Fargo & Company set a $39.00 price target on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Friday, October 6th. Northland Securities reaffirmed a “buy” rating and issued a $40.00 price target on shares of Flexion Therapeutics in a report on Wednesday, October 4th. Finally, Royal Bank Of Canada set a $44.00 price target on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Monday, September 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Flexion Therapeutics currently has an average rating of “Buy” and an average price target of $98.33.
Institutional investors have recently bought and sold shares of the stock. Fiduciary Trust Co. purchased a new stake in Flexion Therapeutics in the 2nd quarter worth about $101,000. IFP Advisors Inc raised its position in Flexion Therapeutics by 24.5% in the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 1,000 shares during the period. Advisor Group Inc. raised its position in Flexion Therapeutics by 205.9% in the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after purchasing an additional 3,500 shares during the period. SG Americas Securities LLC purchased a new stake in Flexion Therapeutics in the 3rd quarter worth about $135,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in Flexion Therapeutics in the 3rd quarter worth about $235,000. 72.82% of the stock is currently owned by institutional investors.
Shares of Flexion Therapeutics (NASDAQ FLXN) traded down $0.26 during trading hours on Friday, hitting $25.44. 756,041 shares of the company were exchanged, compared to its average volume of 848,101. The company has a quick ratio of 12.93, a current ratio of 12.93 and a debt-to-equity ratio of 0.87. Flexion Therapeutics has a 1 year low of $16.51 and a 1 year high of $32.25.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.